mutation.
“What does this mean?”
“It means their leukemia isn’t behaving like ordinary leukemia.”
“How do you know?”
“Because Genevieve knew.”
My eyes lifted.
Elena glanced toward the hallway as if expecting someone to appear.
“She knew before they were born.”
I stood very slowly.
“Start talking.”
Elena remained silent for several seconds.
Then she said, “Your wife saved my life.”
I waited.
“Seven years ago I was twenty three.
I was sleeping in shelters and working nights at a diner.
I had a younger sister named Sofia.
She was sixteen and sick with a rare blood disorder.
We had no insurance.
No family.
No money.
A doctor told us about a research program offering free treatment in exchange for genetic testing.”
“Where?”
“Helixor Biomedical.”
I knew the name.
Helixor was a small medical research company my holding group had invested in years earlier.
At the time, the investment had
